USO 24154
A Multicenter, randomized, open label, Phase 3 Trial of Trastuzumab Deruxtecan (ENHERTU®) plus chemotherapy plus or minus Pembrolizumab versus chemotherapy plus Trastuzumab plus or minus Pembrolizumab as first line treatment in participants with unresectable, locally advanced or metastatic HER2-postive Gastric or GEJ cancer. (Destiny- Gastric05) (Trial of Trastuzumab Deruxtecan (ENHERTU®) plus chemotherapy plus or minus Pembrolizumab versus chemotherapy plus trastuzumab plus or minus Pembrolizumab in first line metastatic HER2-positive gastric or GEJ cancer) (DS8201-724)
Disease Types: Gastrointestinal Cancer Research
Eligibility Requirements:
• Previously untreated, unresectable, locally advanced or
metastatic HER2-positive gastric or GEJ cancer
• Centrally determined tumor PD-L1 CPS
• Main Cohort: PD-L1 CPS ≥1
• Exploratory Cohort: PD-L1 CPS <1
• Must provide a tumor sample for tissue-based IHC staining
• At least 1 target measurable lesion on CT or MRI
• Subjects with prior exposure to HER2-targeted therapy are
excluded
• Subjects with known DPD enzyme deficiency are excluded
For more information on this trial CLICK HERE .
Available at: